AIM: To investigate the impact of high-dose hepatitis B immunoglobulin（HBIG） on hepatocellular carcinoma（HCC） and hepatitis B virus（HBV） recurrence and overall survival after living donor liver transplantation（LDLT）.METHODS: We investigated 168 patients who underwent LDLT due to HCC, and who were HBV-DNA/hepatitis B e antigen（HBe Ag）-positive, from January 2008 to December 2013. After assessing whether the patients met the Milan criteria, they were assigned to the low-dose HBIG group and high-do... 

【文章來源】：World Journal of Gastroenterology. 2016,22(14)

【文章頁數(shù)】：10 頁


本文編號：3494756